Serine determines tissue targeted efficacy of PKM2 modulators in atopic dermatitis

Imagine your body's immune system as a massive, bustling army. When a threat appears—like a virus or an allergen—this army needs to grow rapidly, build weapons, and launch attacks. To do this, the soldiers (immune cells) need a massive amount of energy and building blocks. They get this energy by eating sugar and running it through a metabolic assembly line called glycolysis. One of the most important machines on this line is a protein called PKM2. Think of PKM2 as a traffic cop at a busy intersection. Sometimes, this cop is lazy and lets traffic flow slowly, which is great for resting cells. But when the immune system needs to fight, PKM2 gets "switched on" to a super-fast mode, helping cells multiply and release inflammatory signals.

However, there's a catch. In some diseases, like a very itchy, red skin condition called atopic dermatitis (eczema), the immune cells get stuck in this "fight mode" and won't stop, causing chronic inflammation. Scientists have been trying to find a way to flip the switch back to "rest mode" to calm the immune system down. They found a tool that could do this, but it had a weird problem: it worked great in a test tube but failed to fix the problem in living animals. This paper sets out to solve that mystery. It asks: Why does the switch work in the lab but not in the real world? The answer turns out to be a hidden ingredient in the diet of these cells: an amino acid called serine.

---

The Mystery of the Broken Switch

For a while, scientists had a tool called TEPP-46. This molecule was designed to act like a key, forcing the PKM2 traffic cop into its "super-fast" tetramer shape. In theory, this should stop immune cells from growing out of control. And in the test tube, it worked perfectly. But when researchers tried to use it in mice with inflamed skin, it didn't work at all. It was like having a key that opened a door in a drawing, but the door was locked tight in the real house.

The authors of this study, led by researchers from Trinity College Dublin and Sitryx Therapeutics, decided to investigate why this disconnect happened. They suspected the problem wasn't the key itself, but the environment where the key was being used. Specifically, they looked at serine, a building block that immune cells need to make DNA and proteins.

The Serine Shortage Secret

The researchers discovered that the "broken switch" mystery was actually a case of serine demand.

In the standard test tubes scientists use, the liquid medium is packed with serine—way more than what you'd find in real human tissue. It's like trying to test a car's fuel efficiency while it's parked in a garage full of gas. In this "high-serine" environment, the immune cells are so well-fed that they don't care if you speed up their metabolism; they just keep growing.

But in the real world, and specifically in the skin of people with atopic dermatitis, the situation is different. The inflamed skin is a place of high demand. The immune cells there are hungry for serine, and the local supply is actually quite low.

The team developed a new, better drug called SYX-PKM-A. This drug is an oral medication (a pill you can swallow) that, like TEPP-46, forces PKM2 into its fast, active shape. When they tested SYX-PKM-A on human immune cells in a "low-serine" environment (mimicking the real inflamed skin), the results were dramatic.

Here is the magic trick: By forcing PKM2 to work at full speed, the drug diverts a key ingredient called 3-phosphoglycerate (3-PG) away from making serine and toward making energy (pyruvate).

• In a high-serine lab: The cells have plenty of serine from the outside, so they don't care that the factory stopped making it. The drug does nothing.
• In a low-serine environment (like inflamed skin): The cells are already starving for serine. When the drug cuts off their internal production line, they hit a wall. They can't make enough DNA to multiply, and they can't make enough antibodies. They essentially run out of fuel and stop attacking.

The authors proved this by adding formate (a chemical cousin of serine) to the mix. When they gave the starving cells formate, the drug stopped working, and the cells started growing again. This confirmed that the drug works by creating a "serine shortage" that only affects cells in high-demand environments.

The Results: A Targeted Solution

The study showed that SYX-PKM-A is incredibly effective at stopping the growth of various trouble-making immune cells, including:

• Th2 cells: The main drivers of allergic reactions and eczema.
• Th17 cells: Cells involved in chronic inflammation.
• B cells: The factories that make antibodies (including the IgE antibodies that cause allergic itching).

In the lab, the drug was potent at very low concentrations (nanomolar levels), but only when serine was scarce.

But the real test was in the mice. The researchers used three different models of skin inflammation:

1. DNFB Model: A chemical that causes an itchy, red rash.
2. KLH Model: A delayed allergic reaction.
3. House Dust Mite Model: A chronic asthma and skin allergy model.

In all three cases, giving the mice SYX-PKM-A reduced the swelling and inflammation just as well as, or sometimes better than, baricitinib (a powerful, approved drug for eczema) and even a specialized antibody that blocks IL-13.

Crucially, the drug worked because the inflamed skin in these mice had low serine levels and high PKM2 levels, exactly matching the "high demand" profile the researchers predicted. The drug didn't just randomly shut down the immune system; it targeted the specific metabolic weakness of the cells in the inflamed tissue.

Why This Matters

This paper solves a long-standing puzzle in immunology: why some drugs work in a dish but fail in a body. The answer is that the "diet" of the tissue matters. The authors suggest that serine demand is the key that determines whether a PKM2 modulator will work.

For patients with atopic dermatitis, this is a big deal. Currently, the best oral treatments are JAK inhibitors, which can have serious side effects and are often reserved for severe cases. SYX-PKM-A offers a new path. Because it targets a metabolic weakness specific to the inflamed tissue, it might be safer and more effective, acting like a sniper that only hits the hungry, overactive cells while leaving the rest of the immune system alone.

The study confirms that the drug works in mice and in human cells, and a version of this drug (SYX-5219) has already entered clinical trials in humans. It's a promising step toward a new kind of treatment that doesn't just suppress the immune system, but outsmarts it by cutting off its supply lines right where the battle is being fought.